Pregled bibliografske jedinice broj: 1282170
Cholinesterase inhibitors as drugs for Alzheimer's disease
Cholinesterase inhibitors as drugs for Alzheimer's disease // Book of Abstracts Proceedings of 59th Meeting of the Serbian Chemical Society / Šojić Merkulov, Daniela (ur.).
Beograd: Serbian Chemical Society, 2023. str. 27-27 (plenarno, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 1282170 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Cholinesterase inhibitors as drugs for Alzheimer's
disease
Autori
Bosak, Anita
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Book of Abstracts Proceedings of 59th Meeting of the Serbian Chemical Society
/ Šojić Merkulov, Daniela - Beograd : Serbian Chemical Society, 2023, 27-27
ISBN
978-86-7132-081-8
Skup
59th Meeting of the Serbian Chemical Society
Mjesto i datum
Beograd, Srbija, 01.06.2023. - 02.06.2023
Vrsta sudjelovanja
Plenarno
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Alzheimer`s disease ; acetylcholinesterase ; butyrylcholinesterase ; multi-target-directed ligands ; beta secretase 1
Sažetak
Alzheimer's disease (AD) is a neurodegenerative disease with a complex pathophysiology, which despite the significant progress in the field, remains unclear. During the years, a few hypotheses to explain the disease’s progress were developed. The most widespread is cholinergic hypothesis, which assumes that memory impairments in AD are associated with decreased brain levels of the neurotransmitter acetylcholine leading to decline in memory, problems with communication, memory, orientation and judgment. In line with this hypothesis, the inhibition of enzymes involved in acetylcholine breakdown, acetylcholinesterase and butyrylcholinesterase, represents the mainstream in treatment of neurodegenerative diseases associated with declined levels of acetylcholine. Although the complex and multi-layered pathophysiology of AD led to redirecting the ‘magic bullet’ concept of treatment strategy toward the „multi- target-directed ligands“ concept, cholinesterase inhibition remains the most desirable trait of any potential drug candidate. Compounds based on a quinoline structure and compounds with carbamate functionality represent a very promising structural base for development of MTDL compounds due to their high inhibition potency towards human cholinesterases, and ability to act as metal chelators and inhibitors of beta secretase 1 as an additional beneficial activity.
Izvorni jezik
Engleski
Znanstvena područja
Kemija, Farmacija
POVEZANOST RADA
Projekti:
HRZZ-IP-2020-02-9343 - Razvoj bioaktivnih molekula za tretman neurodegenerativnih bolesti (BioMol4ND) (Bosak, Anita, HRZZ - 2020-02) ( CroRIS)
Ustanove:
Institut za medicinska istraživanja i medicinu rada, Zagreb
Profili:
Anita Bosak (autor)